The aim of WP3 is to develop human-relevant test systems to identify ED for metabolic disorders. OBERON will use next generation of cellular toxicity assays by developing innovative technological issues. Different cell systems will be developed from 2D models to 3D cultures which reflect more accurately the organ functionality. Integrative cellular models will be established by developing different co-culture models and extracellular vesicles as potential biomarkers for endocrine disruption will be also implemented. Together with omics profiling, this will support the evaluation of possible EDs effects on metabolic disorders and help establish useful tests for the ITS.